Th22 and related cytokines in inflammatory and autoimmune diseases

被引:75
作者
Tian, Tian [1 ]
Yu, Shuang [1 ]
Ma, Daoxin [1 ]
机构
[1] Shandong Univ, Qilu Hosp, Dept Hematol, Jinan 250012, Peoples R China
关键词
IL-22; inflammatory and autoimmune diseases; Th22; therapeutic perspectives; SYSTEMIC-LUPUS-ERYTHEMATOSUS; CD4(+) T-CELLS; PROINFLAMMATORY GENE-EXPRESSION; MUCOSAL HOST-DEFENSE; GROWTH-FACTOR-I; RHEUMATOID-ARTHRITIS; TH17; CELLS; CROHNS-DISEASE; INDUCIBLE FACTOR; INTERLEUKIN; 22;
D O I
10.1517/14728222.2013.736497
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Introduction: Th22 and related cytokines regulate various processes and have been linked to diverse effects. The levels of Th22 and cytokine IL-22 are increased in several disorders and positively related to some autoimmune diseases. Preclinical studies have suggested that the inhibition or stimulation of IL-22 is an attractive approach to reverse the immune disorders. Simultaneously, considering many patients with refractory autoimmune diseases respond poorly to the therapies which are highly toxic, more effective therapies are to be examined. Areas covered: The role of Th22 cells and related cytokines and therapeutic strategies targeting them in many illnesses, especially inflammatory and autoimmune diseases. Expert opinion: Th22 cells and related cytokine IL-22 regulate multiple biological functions and play an important role in a number of inflammatory and autoimmune diseases. They have unique and attractive advantages for targeting. Targeting IL-22 has already been trialed in many mice experiments, showing better efficacy and fewer side effects compared with classical drugs. Targeting IL-22 or Th22 might provide pathogenetic treatment. However, Th22 subset is a recently identified Th subset and its associated research is extremely limited. Therefore, there are still many unanswered questions and further researches are warranted.
引用
收藏
页码:113 / 125
页数:13
相关论文
共 130 条
[1]
Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis [J].
Abdollahi-Roodsaz, Shahla ;
Joosten, Leo A. B. ;
Koenders, Marije I. ;
Devesa, Isabel ;
Roelofs, Mieke F. ;
Radstake, Timothy R. D. J. ;
Heuvelmans-Jacobs, Marleen ;
Akira, Shizuo ;
Nicklin, Martin J. H. ;
Ribeiro-Dias, Fatima ;
Van den Berg, Wim B. .
JOURNAL OF CLINICAL INVESTIGATION, 2008, 118 (01) :205-216
[2]
Acinar cells of the pancreas are a target of interleukin-22 [J].
Aggarwal, S ;
Xie, MH ;
Maruoka, M ;
Foster, J ;
Gurney, AL .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2001, 21 (12) :1047-1053
[3]
Akaqawa KS, 2012, KEKKAKU, V87, P61
[4]
Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-γ- and interleukin-4-induced activation of human keratinocytes [J].
Albanesi, C ;
Scarponi, CS ;
Cavani, A ;
Federici, M ;
Nasorri, F ;
Girolomoni, G .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2000, 115 (01) :81-87
[5]
ALMUS FE, 1991, BLOOD, V77, P1256
[6]
Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts [J].
Andoh, A ;
Zhang, ZB ;
Inatomi, O ;
Fujino, S ;
Deguchi, Y ;
Araki, Y ;
Tsujikawa, T ;
Kitoh, K ;
Kim-Mitsuyama, S ;
Takayanagi, A ;
Shimizu, N ;
Fujiyama, Y .
GASTROENTEROLOGY, 2005, 129 (03) :969-984
[7]
Heterogeneity of human effector CD4+ T cells [J].
Annunziato, Francesco ;
Romagnani, Sergio .
ARTHRITIS RESEARCH & THERAPY, 2009, 11 (06)
[8]
INHIBITION OF THE PRODUCTION AND EFFECTS OF INTERLEUKIN-1 AND TUMOR-NECROSIS-FACTOR-ALPHA IN RHEUMATOID-ARTHRITIS [J].
AREND, WP ;
DAYER, JM .
ARTHRITIS AND RHEUMATISM, 1995, 38 (02) :151-160
[9]
IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia [J].
Aujla, Shean J. ;
Chan, Yvonne R. ;
Zheng, Mingquan ;
Fei, Mingjian ;
Askew, David J. ;
Pociask, Derek A. ;
Reinhart, Todd A. ;
McAllister, Florencia ;
Edeal, Jennifer ;
Gaus, Kristi ;
Husain, Shahid ;
Kreindler, James L. ;
Dubin, Patricia J. ;
Pilewski, Joseph M. ;
Myerburg, Mike M. ;
Mason, Carol A. ;
Iwakura, Yoichiro ;
Kolls, Jay K. .
NATURE MEDICINE, 2008, 14 (03) :275-281
[10]
Bernardi RJ, 2001, CLIN CANCER RES, V7, P4164